Agenus Inc. (AGEN) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Garo H. Armen	Founder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman	1.21M	1953
Jennifer S. Buell	Director and President & Chief Executive Officer of MiNK Therapeutics	0	1975
Steven J. O'Day	Chief Medical Officer	902,820	1961
Austin Charette	Senior Director, Financial Reporting and Compliance & Principal Accounting Officer	0	1989
Kamel Djazouli	Head of Medical Affairs	0	N/A
Stefanie Perna-Nacar	Chief Communications & Government Relations Officer	0	N/A
Zack Armen	Vice President of Investor Relations & Corporate Development	0	N/A
Robin G. Taylor	Chief Commercial Officer	0	N/A
Tracy Mazza Clemente	Chief People Officer	0	N/A
Craig Winter	Chief Information Officer	0	N/A
Todd Jude Yancey	Member of Advisory Board & Chief Strategic Advisor	0	N/A

Name

Title

Pay

Year Born

Garo H. Armen

Founder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman

1.21M

1953

Jennifer S. Buell

Director and President & Chief Executive Officer of MiNK Therapeutics

1975

Steven J. O'Day

Chief Medical Officer

902,820

1961

Austin Charette

Senior Director, Financial Reporting and Compliance & Principal Accounting Officer

1989

Kamel Djazouli

Head of Medical Affairs

N/A

Stefanie Perna-Nacar

Chief Communications & Government Relations Officer

N/A

Zack Armen

Vice President of Investor Relations & Corporate Development

N/A

Robin G. Taylor

Chief Commercial Officer

N/A

Tracy Mazza Clemente

Chief People Officer

N/A

Craig Winter

Chief Information Officer

N/A

Todd Jude Yancey

Member of Advisory Board & Chief Strategic Advisor

N/A

Description

Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.